Form 4: Voyager Therapeutics Director Jude Onyia Granted 24,000 Stock Options

Voyager Therapeutics, Inc. director Jude Onyia was granted 24,000 stock options at an exercise price of $3.28, aligning his interests with long-term shareholder value.

Summary

• Jude Onyia, a Director of Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options.
• The options have an exercise price of $3.28 per share.
• The transaction date for this grant was June 3, 2025.
• The options were issued under the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc., consistent with its director compensation policy.
• The vesting commencement date is the grant date, June 3, 2025.
• All shares underlying the option will vest upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, subject to Mr. Onyia's continued service as a director.
• The expiration date for these stock options is June 3, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholder value, reflecting standard corporate governance practices. It is not a major market-moving event but indicates stable compensation practices.

Positives

• The grant of stock options to Director Jude Onyia aligns his financial interests with the long-term performance and shareholder value of Voyager Therapeutics, Inc.
• This transaction is part of a pre-established director compensation policy and the 2025 Stock Incentive Plan, indicating structured corporate governance regarding executive and director incentives.

Future Outlook

The vesting schedule of the granted stock options indicates an expectation of continued service from Director Jude Onyia, with full vesting occurring within one year or by the next annual meeting, subject to his ongoing role.

Management Comments

• The stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning leadership's interests with long-term company performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in the biotech sector, where equity incentives are crucial for aligning long-term interests.
• The vesting schedule, tied to continued service and annual meetings, is typical for director equity awards, similar to practices observed at companies like Biogen Inc. or Sarepta Therapeutics, Inc., which also utilize performance-based or time-based equity grants for their board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jude Onyia, a director of Voyager Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.
• Director (Jude Onyia): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The stock options will vest upon the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date of the next annual meeting of stockholders, contingent on continued service.

Key Dates

Recommendation

Keywords

Voyager Therapeutics, VYGR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Jude Onyia